What is the Principle of Olink?
The Principle of Olink Technology
Olink employs the Proximity Extension Assay (PEA), a technology with proprietary intellectual property. In this method, a pair of antibodies, each equipped with a unique nucleotide sequence probe, specifically binds to the target protein. After correct binding, the proximity probes at the ends of the antibodies form a complementary 5-base pair bond. This results in the formation of a double-stranded template, catalyzed by a polymerase enzyme. Detection is then performed using qPCR or NGS, where the specific nucleotide sequence signal directly correlates with the protein concentration being measured. The principle of Olink technology relies on antibody-based detection, combined with a powerful amplification process that enables highly sensitive quantification of proteins in complex biological samples.
Experimental Method (Site_B Baseline 20200001)
Our research team utilized Olink's Proximity Extension Assay (PEA) technology and the NPX Manager software to design experiments, implement assays, preprocess data, and perform preliminary analyses for the target proteins requested by the client. PEA is an innovative technique that combines protein-antibody immune reaction with oligonucleotide amplification to detect and quantify proteins. The method was developed to identify protein biomarkers. The principle of Olink technology, with its focus on precise protein detection, makes it a valuable tool for studying biomarker profiles across diverse clinical conditions. Olink offers customizable protein panels, with current services including Olink Target 96 and Olink Explore 384 products. The Olink Target 96 product includes cancer biomarker panels (Oncology Panel), cardiometabolic protein panels (Cardiometabolic Panel), metabolism-related protein panels (Metabolism Panel), inflammation-related protein panels (Inflammation Panel), and 14 human protein detection panels, as well as 1 mouse protein detection panel. Olink Explore 384 includes services for protein quantification in areas such as Cardiometabolic, Inflammation, Neurology, and Oncology.
Characteristics
Traditional proteomics and protein biomarker detection methods are limited by factors such as throughput, sensitivity, and clinical applicability. To address these limitations, Olink Proteomics has developed a mature technical solution with the following key features: the principle of Olink technology provides robust solutions for researchers by ensuring comprehensive detection capabilities.
1. High Throughput
Rapid analysis of 48 to 3072 protein biomarkers across multiple samples.
2. Low Sample Volume
Requires less than 8 microliters of sample (e.g., plasma).
3. Targeted
All proteins detected are biomarkers, covering 100% of signaling pathways (from leading global institutions and experts).
4. High Sensitivity
Detection sensitivity down to fg/ml levels.
5. Wide Dynamic Range
A dynamic range spanning 10 logs, covering proteins with high, medium, and low abundance (particularly low-abundance proteins).
6. Automation
An automated sample processing workflow ensures simplicity, accuracy, and reproducibility.
7. Multi-omics
Multi-omics data can be obtained using a single NGS platform or qPCR system (Signature Q100).
8. Liquid Biopsy
Compatible with various sample types, especially useful for detecting low-abundance proteins in body fluids.
9. Validation and Recognition
Olink Proteomics has been thoroughly validated and recognized by scientists in Europe and the United States, as well as professionals in pharmaceutical and diagnostic fields of precision medicine.
10. Research
Over 2000 published studies have employed Olink technology.
11. Pharmaceutical
Olink technology is already used by the top 20 pharmaceutical companies worldwide.
12. Diagnostics
Diagnostic companies have successfully developed liquid biopsy biomarker panels for complex diseases such as multiple sclerosis using Olink technology.
13. Early Screening
Leading companies in early disease screening are utilizing Olink for the development of early screening products for diseases like cancer.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
